Corixa (company)

Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

This article is about the biotech corporation. For the style fly tying, see Fly lure. For the heteropteran bug family, see Corixidae.
Corixa
Typebiotechnology/pharmaceutical
Successoracquired by GlaxoSmithKline
Founded1994 in Seattle, Washington
DefunctMarch 31, 2006 (2006-03-31)
Headquarters
Seattle
,
Washington
Number of locations
2
ParentGlaxoSmithKline (United States) 

The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.

On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

On 31 March 2006, Corixa's doors closed after over 11 years in business.

  • "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.

References
  1. "Glaxo to acquire Corixa for $300 million". Market Watch. April 29, 2005.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.